PGI7 EVALUATION OF LIVER OUTCOMES RELATIVE TO USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN REAL-WORLD POPULATIONS DIAGNOSED WITH TYPE II DIABETES (T2DM) AND NASH/NAFLD OR AT RISK OF NASH
May 1, 2020, 00:00
10.1016/j.jval.2020.04.365
https://www.valueinhealthjournal.com/article/S1098-3015(20)30553-2/fulltext
Title :
PGI7 EVALUATION OF LIVER OUTCOMES RELATIVE TO USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN REAL-WORLD POPULATIONS DIAGNOSED WITH TYPE II DIABETES (T2DM) AND NASH/NAFLD OR AT RISK OF NASH
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)30553-2&doi=10.1016/j.jval.2020.04.365
First page :
Section Title :
Open access? :
No
Section Order :
10228